Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital ...

Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH), which is expected to begin ...

Rezolute (RZLT) announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, to ersodetug, ...

Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH), which is expected to begin in 2H 2025 Phase 1 trial in healthy volunteers showed MBX 1416 was generall ...

In view of its prompt and sustained effectiveness, diazoxide currently appears to be the agent of choice in the pharmacologic treatment of chronic hypoglycemia in children as well as adults.

- Dan Monahan will lead the commercialization strategy across Amylyx’ product portfolio, beginning with avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor ...

Insulin has long been the typical pharmacological go-to agent for gestational diabetes, the researchers pointed out, but oral ...

Postprandial hypoglycemia is one of the main complications of bariatric surgery and can affect up to 30% of patients. Unlike ...

Nocturnal hypoglycemia refers to low blood glucose levels during sleeping. Regularly monitoring glucose levels and adjusting insulin dosages can help prevent nocturnal hypoglycemia. Nocturnal ...

the same hormones that are elevated in individuals who've developed postprandial hypoglycemia," he says. The researchers then decided to test the use of serotonin antagonists as a treatment ...

Healthcare professionals may recommend ginger for nausea relief, especially for motion sickness, during pregnancy, and when ...

Brittle diabetes is common in people with type 1 or type 2 diabetes. It not only affects older adults, but also teenagers.